Modafinil for neurobehavioural dysfunction in sleep apnea patients who cannot use standard device-based treatments.

莫达非尼用于治疗无法使用标准设备治疗的睡眠呼吸暂停患者的神经行为功能障碍。

• 批准号: nhmrc : 1004528
• 负责人: A/Pr Brendon Yee
• 金额: $ 33.73万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/modafinil-neurobehavioural-dysfunction-based-treatments/109043
• 关键词: Modafinil; neurobehavioural; dysfunction; sleep; apnea

Obstructive sleep apnea (OSA) is often caused by obesity and can result in fall-asleep car crashes. It is often treated by mechanical devices that keep the sleeping airway open. Unfortunately, around half of all patients cannot tolerate these treatments. We propose to help patients reduce obesity with a lifestyle intervention program whilst testing whether their daytime symptoms of sleepiness and poor driving ability can be treated with a wake-promoting drug called modafinil.

阻塞性睡眠呼吸暂停（OSA）通常是由肥胖引起的，并可能导致入睡车祸。它通常通过保持睡眠呼吸道开放的机械装置来治疗。不幸的是，大约一半的患者无法忍受这些治疗。我们建议通过生活方式干预计划帮助患者减少肥胖，同时测试他们白天的嗜睡和驾驶能力差的症状是否可以用一种名为莫达非尼的促醒药物治疗。